- Home
- ESPR vs ARVN Comparison
ESPR vs ARVN Comparison
Compare ESPR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESPR | ARVN |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.7M | 781.0M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESPR | ARVN |
|---|---|---|
| Price | $2.65 | $10.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | $7.60 | ★ $15.35 |
| AVG Volume (30 Days) | ★ 4.6M | 763.2K |
| Earning Date | 03-10-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $403,135,000.00 | $262,600,000.00 |
| Revenue This Year | $0.69 | N/A |
| Revenue Next Year | $10.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.73 | $5.90 |
| 52 Week High | $4.18 | $14.22 |
Technical Indicators
Market Signals| Indicator | ESPR | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 29.80 |
| Support Level | $2.37 | $9.02 |
| Resistance Level | $3.02 | $14.03 |
| Average True Range (ATR) | 0.20 | 0.69 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 38.52 | 2.36 |
Price Performance
Historical ComparisonAbout ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.